Inhibitors and PROTACs of CDK2: challenges and opportunities
Author:
Affiliation:
1. Medical College, Guizhou University, Guiyang, China
2. Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing, China
3. Department of Neurosurgery, Guizhou Provincial People’s Hospital, Guiyang, China
Funder
Guizhou Provincial Basic Research Program
Guizhou University Talent Introduction Research Project
Health Commission of Guizhou Province
National Natural Science Foundation of China
Guizhou Provincial People’s Hospital National Science Foundation
Publisher
Informa UK Limited
Link
https://www.tandfonline.com/doi/pdf/10.1080/17460441.2024.2376655
Reference143 articles.
1. Cyclin-dependent kinases: bridging their structure and function through computations
2. Cyclin-dependent kinase 2 (CDK2) inhibitors and others novel CDK inhibitors (CDKi) in breast cancer: clinical trials, current impact, and future directions
3. Inhibitors of cyclin-dependent kinases as cancer therapeutics
4. From Structure Modification to Drug Launch: A Systematic Review of the Ongoing Development of Cyclin-Dependent Kinase Inhibitors for Multiple Cancer Therapy
5. The Roles of Cyclin-Dependent Kinases in Cell-Cycle Progression and Therapeutic Strategies in Human Breast Cancer
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3